pemetrexed + cisplatin

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neoplasm, Gastric

Conditions

Neoplasm, Gastric

Trial Timeline

Mar 1, 2004 → Jul 1, 2008

NCT ID

NCT00320515

About pemetrexed + cisplatin

pemetrexed + cisplatin is a phase 1/2 stage product being developed by Eli Lilly for Neoplasm, Gastric. The current trial status is completed. This product is registered under clinical trial identifier NCT00320515. Target conditions include Neoplasm, Gastric.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00040625	Pre-clinical	Completed	—	—	Mesothelioma
NCT01000480	Phase 2	Completed	Oct 1, 2009	Jul 1, 2013	Non Small Cell Lung Cancer
NCT00887549	Phase 2	Completed	Apr 1, 2009	Jun 1, 2011	Non-Small Cell Lung Cancer
NCT00895648	Phase 2	Terminated	Jan 1, 2009	Oct 1, 2012	Mesothelioma
NCT00475657	Phase 2	Terminated	Oct 1, 2007	Apr 1, 2008	Small Cell Lung Cancer
NCT00447421	Phase 1/2	Terminated	Feb 1, 2007	May 1, 2008	Small Cell Lung Cancer
NCT00415168	Phase 2	Completed	Dec 1, 2006	Jul 1, 2009	Gastric Cancer
NCT00386815	Phase 2	Completed	Oct 1, 2006	Feb 1, 2007	Malignant Pleural Mesothelioma
NCT00374868	Phase 1/2	Completed	Aug 1, 2006	Apr 1, 2008	Urologic Neoplasms
NCT00259285	Phase 2	Terminated	Nov 1, 2005	Dec 1, 2007	Non-Small-Cell Lung Cancer
NCT00251550	Phase 1/2	Completed	Oct 1, 2005	Aug 1, 2006	Malignant Pleural Mesotherioma
NCT00191308	Phase 2	Completed	May 1, 2005	Dec 1, 2010	Non-Small Cell Lung Cancer
NCT00320515	Phase 1/2	Completed	Mar 1, 2004	Jul 1, 2008	Neoplasm, Gastric
NCT00190801	Phase 2	Completed	Sep 1, 2003	Sep 1, 2005	Gastrointestinal Neoplasms
NCT00087698	Phase 2	Completed	Sep 1, 2003	Feb 1, 2008	Pleural Neoplasms

Competing Products

20 competing products in Neoplasm, Gastric

See all competitors

Product	Company	Stage	Hype Score
AB0024	Gilead Sciences	Phase 1	32
TTI-237	Pfizer	Phase 1	32
852A	Pfizer	Phase 1	32
EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab	CSPC Pharmaceutical Group Limited	Phase 1	32
LY2780301	Eli Lilly	Phase 1	33
Pemetrexed	Eli Lilly	Phase 2	52
IMC-3C5	Eli Lilly	Phase 1	33
LY3295668	Eli Lilly	Phase 1/2	41
Abemaciclib + Clarithromycin	Eli Lilly	Phase 1	33
Abemaciclib + Fulvestrant	Eli Lilly	Phase 2	52
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	41
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	77
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin	Eli Lilly	Phase 1	33
LY2784544	Eli Lilly	Phase 1	33
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
enzastaurin	Eli Lilly	Phase 2	52
enzastaurin + gemcitabine	Eli Lilly	Phase 2	52
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	33
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved